Each group of immunosuppressive agents that have been used in solid organ recipients (corticosteroids, azathioprine, mycophenolate mofetil, calcineurin inhibitors and mTor antagonists) either alone or in combination has been demonstrated to potentiate dyslipidemia and adversely affect long-term allograft outcomes. The gene discussed is MTOR; the disease is metabolic syndrome.